Glucose Dependent Insulinotropic Receptor – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119)- Pipeline Review, H2 2019’, provides in depth analysis on Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Metabolic Disorders and Gastrointestinal under development targeting Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119)

– The report reviews Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics and enlists all their major and minor projects

– The report assesses Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Arena Pharmaceuticals Inc

CymaBay Therapeutics Inc

Dong-A Socio Holdings Co Ltd

Hyundai Pharmaceutical Co Ltd

Japan Tobacco Inc

Kowa Co Ltd

Merck & Co Inc

Novartis AG

Scohia Pharma Inc

Taisho Pharmaceutical Holdings Co Ltd”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Overview

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Companies Involved in Therapeutics Development

Amgen Inc

Arena Pharmaceuticals Inc

CymaBay Therapeutics Inc

Dong-A Socio Holdings Co Ltd

Hyundai Pharmaceutical Co Ltd

Japan Tobacco Inc

Kowa Co Ltd

Merck & Co Inc

Novartis AG

Taisho Pharmaceutical Holdings Co Ltd

Yuhan Corp

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Drug Profiles

APD-597 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DA-1241 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HOB-047 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MBX-2982 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCO-094 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GPR119 for Type 2 Diabetes Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GPR119 for Type 2 Diabetes Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GPR119 Receptor for Unspecified Indication Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GRP119 for Type 2 Diabetes and Obesity Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize GPR119 for Type 2 Diabetes Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize GPR119 for Type 2 Diabetes Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize GPR119 for Type 2 Diabetes Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize GPR119 Receptor for Type 2 Diabetes Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YH-18420 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Dormant Products

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Discontinued Products

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Product Development Milestones

Featured News & Press Releases

Nov 04, 2010: Arena Pharmaceuticals Provides Update On GPR119 Portfolio For Type 2 Diabetes

Nov 05, 2009: Metabolex Closes $8.6 Million Financing Round

Dec 15, 2008: Arena Pharmaceuticals Announces Initiation Of Phase I Clinical Trial Of Type 2 Diabetes Drug Candidate In Partnership With Ortho-McNeil-Janssen Pharmaceuticals

Nov 12, 2008: Metabolex Announces Positive Results From Phase 1a Clinical Trial Of MBX-2982

Mar 26, 2008: Metabolex, Inc. Initiates Phase 1 Trial Of MBX-2982

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Arena Pharmaceuticals Inc, H2 2019

Pipeline by CymaBay Therapeutics Inc, H2 2019

Pipeline by Dong-A Socio Holdings Co Ltd, H2 2019

Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2019

Pipeline by Japan Tobacco Inc, H2 2019

Pipeline by Kowa Co Ltd, H2 2019

Pipeline by Merck & Co Inc, H2 2019

Pipeline by Novartis AG, H2 2019

Pipeline by Scohia Pharma Inc, H2 2019

Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports